Table 4.
Risk score at baseline and 12 months of follow up stratified by study cohort and population (means and medians)
| Population | Study | Risk score at baseline | Risk score at 12 months | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | Median | IQR | Mean | SD | Median | IQR | ||
| FF | Non-SiVET1 | 7.7 | 3.9 | 8 | 5–10 | 5.1 | 3.6 | 4 | 2–7 |
| SiVET1 | 8.8 | 3.6 | 9 | 6–11 | 4.8 | 3.2 | 5 | 2–7 | |
| FSW | Non-SiVET2 | 8.7 | 2.7 | 9 | 7–10 | 8.5 | 2.5 | 9 | 7–10 |
| SiVET2 | 11.4 | 3.1 | 9 | 8–13 | 9.5 | 3.8 | 10 | 7–12 | |
FF Fisherfolk, FSW female sex worker, SiVET simulated vaccine efficacy trial, SD standard deviation, IQR interquartile range